Trial Profile
Randomized phase II trial of cetuximab with and without weekly paclitaxel in patients with previously treated advanced urothelial cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Paclitaxel (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 27 Aug 2012 Status changed from active, no longer recruiting to completed, based on results reported in the Journal of Clinical Oncology.
- 27 Aug 2012 Primary endpoint 'Progression-free-survival-duration' has been met.
- 27 Aug 2012 Results published in the Journal of Clinical Oncology.